Table 8.

Odds Ratios (ORs) and 95% CI of Performance Status Benefit Associated With Different Dosage of Aidi Injection in the Stratified Analysis.

	Non-Aidi Use (N = 1600)	Aidi Use
		Less Than Conventional Dosage (n = 183)		Conventional Dosage (n = 1417)
	OR	OR (95% CI)	P a	OR (95% CI)	P a
Variable
Gender
Female	[reference]	2.0 (0.6-5.9)	.238	2.2 (1.7-2.9)	<.001
Male	[reference]	1.2 (1.1-1.6)	<.001	1.5 (1.2-1.8)	<.001
Age, years
⩽60	[reference]	1.5 (1.2-1.9)	<.001	2.0 (1.6-2.6)	<.001
>60	[reference]	1.7 (0.6-4.5)	.297	1.6 (1.2-2.0)	<.001
Body mass index, kg/m2
<18.5	[reference]	4.4 (0.8-25.3)	.094	2.9 (1.5-5.0)	<.001
18.5-24	[reference]	2.6 (1.3-5.4)	.009	1.5 (1.2-1.8)	<.001
>24	[reference]	1.3 (0.9-4.3)	.252	2.1 (1.4-3.2)	<.001
Tumor type
Gastric cancer	[reference]	6.0 (2.4-15.0)	<.001	2.1 (1.4-2.9)	<.001
Lung cancer	[reference]	1.1 (0.2-4.9)	.912	1.4 (1.0-1.9)	.029
Breast cancer	[reference]	1.6 (1.1-2.3)	<.001	1.9 (1.3-2.8)	.002
Colorectal cancer	[reference]	1.4 (0.9-3.3)	.792	1.8 (1.1-3.6)	<.001
Cardiac and esophageal cancer	[reference]	12.1 (0.9-143.0)	.057	3.0 (1.0-8.9)	.042
Hepatobiliary cancer	[reference]	1.3 (0.6-9.7)	.891	0.8 (0.3-1.8)	0.591
Ovarian cancer	[reference]	2.2 (1.6-3.3)	.042	2.5 (1.1-5.6)	.026
TNM stage
I-II	[reference]	2.1 (0.4-10.2)	.357	1.7 (1.1-2.5)	.009
III-IV	[reference]	1.3 (1.1-1.7)	<.001	1.8 (1.5-2.2)	<.001
Node metastasis
Negative	[reference]	1.6 (1.4-1.9)	<.001	1.7 (1.4-2.1)	<.001
Positive	[reference]	0.9 (0.1-7.4)	.936	1.9 (1.3-2.8)	<.001
Distant metastasis
Negative	[reference]	1.3 (1.2-1.6)	.018	1.8 (1.5-2.2)	<.001
Positive	[reference]	1.3 (0.2-11.0)	.782	1.4 (0.9-2.2)	.145
Prior chemotherapy
No	[reference]	1.4 (0.5-3.8)	.476	1.7 (1.3-2.1)	<.001
Yes	[reference]	3.7 (1.5-9.2)	.004	1.9 (1.5-2.5)	<.001
ECOG score
0-1	[reference]	1.4 (1.3-1.7)	<.001	1.8 (1.5-2.1)	<.001
⩾2	[reference]	0.9 (0.3-1.6)	.496	1.2 (0.5-2.6)	.733
Hypertension
No	[reference]	1.4 (1.2-1.9)	<.001	1.9 (1.6-2.3)	<.001
Yes	[reference]	2.0 (0.4-9.7)	.395	1.3 (0.9-1.9)	.181
Renal insufficiency
No	[reference]	1.4 (1.3-1.7)	<.001	1.8 (1.5-2.1)	<.001
Yes	[reference]	0.4 (0.2-0.8)	.797	0.8 (0.2-2.8)	.731
Hepatic insufficiency
No	[reference]	1.4 (1.3-4.7)	.008	1.8 (1.5-2.2)	<.001
Yes	[reference]	1.1(0.9-2.9)	.594	1.4 (0.8-2.6)	.265
Diabetes
No	[reference]	1.5 (1.3-1.8)	<.001	1.9 (1.6-2.2)	<.001
Yes	[reference]	0.6 (0.4-1.9)	.395	0.8 (0.4-1.6)	.484
Chemotherapy regimen
Platinum and fluorouracil based	[reference]	3.5 (1.4-8.7)	.006	1.8 (1.4-2.4)	<.001
Platinum and pemetrexed based	[reference]	6.7 (1.0-46.0)	.054	2.2 (1.1-4.2)	.018
Irinotecan and fluorouracil based	[reference]	3.2 (0.6-17.6)	.185	1.2 (1.0-1.8)	.042
Platinum and taxane based	[reference]	2.8 (1.1-4.9)	.045	3.2 (1.1-9.2)	.033
Cyclophosphamide and adriamycin based	[reference]	1.7 (1.3-3.4)	.037	2.5 (1.2-5.6)	.019
Targeted therapy and others regimen	[reference]	0.5 (0.1-4.1)	.542	1.6 (1.2-2.1)	.002
Other Chinese medicine
ShenqiFuzheng injection
No	[reference]	1.4 (1.2-1.7)	<.001	1.7 (1.4-2.1)	<.001
Yes	[reference]	1.8 (0.8-4.2)	.152	1.9 (1.4-2.6)	<.001
Glycopeptide injection
No	[reference]	2.4 (1.1-5.0)	.026	1.7 (1.4-2.1)	<.001
Yes	[reference]	2.1 (0.6-7.5)	.275	1.9 (1.3-2.6)	<.001
Kushen injection
No	[reference]	1.9 (0.9-4.1)	.083	1.8 (1.5-2.2)	<.001
Yes	[reference]	5.5 (1.3-22.3)	.018	1.5 (1.1-2.2)	.038
Shenmai injection
No	[reference]	1.5 (1.2-1.7)	<.001	1.7 (1.4-2.0)	<.001
Yes	[reference]	3.2 (1.6-7.2)	.042	3.9 (1.4-10.9)	.009
DiyuShengbai tablet
No	[reference]	1.3 (1.2-1.7)	.011	1.7 (1.5-2.1)	<.001
Yes	[reference]	1.7 (1.2-4.8)	.023	2.5 (1.1-7.2)	<.001
Chemotherapy cycle
1-3	[reference]	1.3 (0.4-3.8)	.631	1.7 (1.4-2.2)	<.001
>3	[reference]	4.1 (1.7-9.6)	.001	1.8 (1.4-2.3)	<.001

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

^aBoldfaced P values are statistically significant.